AbbVie News Center - News
WEB2 days ago · AbbVie News Center - News. Latest news. September 27, 2024. AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer. September 26, 2024.
AbbVie Inc. (ABBV) Latest Stock News & Headlines - Yahoo Finance
WEBGet the latest AbbVie Inc. (ABBV) stock news and headlines to help you in your trading and investing decisions.
AbbVie to Acquire ImmunoGen, including its Flagship ... - News
WEBNov 30, 2023 · The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
AbbVie Completes Acquisition of Cerevel Therapeutics
WEBAugust 01, 2024. AbbVie Completes Acquisition of Cerevel Therapeutics. Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease.
AbbVie takes $2.1 bln charge on cancer drug ahead of US price ...
WEBOct 27 (Reuters) - AbbVie (ABBV.N), girding for government price negotiations on its big-selling cancer drug Imbruvica, on Friday disclosed a $2.1 billion charge related to an expected drop in...
AbbVie’s fourth-quarter sales top estimates despite plunging ...
WEBFeb 2, 2024 · AbbVie Inc. ABBV on Friday reported fourth-quarter sales that topped analysts’ estimates, even as it faces low-cost competition for its top-selling drug, Humira. The drugmaker reported...
AbbVie confident of blockbuster drug replacements, lifts ...
WEBOct 29, 2021 · U.S. drugmaker AbbVie Inc on Friday raised its 2021 adjusted profit forecast for the third time this year and said it expects its newer drugs to recreate the success of its blockbuster treatment...
AbbVie Inc. (ABBV) Latest Press Releases & Corporate News ...
WEBGet the latest AbbVie Inc. (ABBV) stock news and headlines to help you in your trading and investing decisions.
EU withdraws marketing authorisation for Abbvie's hepatitis C ...
WEB1 day ago · (Reuters) - The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug Exviera at the request of the company. The regulator...
AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo ...
WEBFind the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.